INCY - CONSENSUS CO - Incyte Corporation

Incyte Corporation (INCY) is expanding drug development through partnerships with global pharma behemoths and joint trials in medical centers. This price chart reflects the current consensus at 129.02. The business relies on a closed hematology treatment system protected by patents. The company is currently overcoming a stagnation in its primary cycle by introducing new dermatological agents to protect revenue from future generics.

This indicator provides a weighted average fair value assessment of the asset from leading investment houses, allowing market noise to be filtered out from long-term fundamental expectations. By analyzing the median analyst price target, an investor can evaluate the growth potential of Incyte Corporation (INCY) shares against the risks of revenue dependence on a single drug and the uncertainty surrounding the outcomes of the company's new clinical trials.